Pathfinder Cell Therapy, Inc.
PFND
$0.00
$0.000.00%
OTC PK
| 09/30/2015 | 06/30/2015 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.97% | -39.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.14% | -29.41% | |||
| Operating Income | -45.14% | 29.41% | |||
| Income Before Tax | -30.18% | 19.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.18% | 19.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.18% | 19.57% | |||
| EBIT | -45.14% | 29.41% | |||
| EBITDA | -45.45% | 29.56% | |||
| EPS Basic | -33.33% | 25.00% | |||
| Normalized Basic EPS | -50.00% | 33.33% | |||
| EPS Diluted | -33.33% | 25.00% | |||
| Normalized Diluted EPS | -50.00% | 33.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||